LTR Pharma Ltd
LTP
Company Profile
Business description
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men’s health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on the market.
Contact
9A/204 Alice Street
BrisbaneQLD4000
AUST: +61 1800519711
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
Another incredible quarter from Microsoft
We were wrong when we thought last quarter would be hard to top.
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,917.10 | 81.90 | -0.91% |
CAC 40 | 7,546.16 | 225.81 | -2.91% |
DAX 40 | 23,425.97 | 639.50 | -2.66% |
Dow JONES (US) | 43,588.58 | 542.40 | -1.23% |
FTSE 100 | 9,068.58 | 64.23 | -0.70% |
HKSE | 24,507.81 | 265.52 | -1.07% |
NASDAQ | 20,650.13 | 472.31 | -2.24% |
Nikkei 225 | 40,799.60 | 270.22 | -0.66% |
NZX 50 Index | 12,729.40 | 94.34 | -0.74% |
S&P 500 | 6,238.01 | 101.38 | -1.60% |
S&P/ASX 200 | 8,662.00 | 80.80 | -0.92% |
SSE Composite Index | 3,559.95 | 13.26 | -0.37% |